These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10097145)

  • 61. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.
    Pai LH; FitzGerald DJ; Tepper M; Schacter B; Spitalny G; Pastan I
    Cancer Res; 1990 Dec; 50(24):7750-3. PubMed ID: 2253218
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.
    McHugh L; Hu S; Lee BK; Santora K; Kennedy PE; Berger EA; Pastan I; Hamer DH
    J Biol Chem; 2002 Sep; 277(37):34383-90. PubMed ID: 12119300
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
    J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.
    Roscoe DM; Jung SH; Benhar I; Pai L; Lee BK; Pastan I
    Infect Immun; 1994 Nov; 62(11):5055-65. PubMed ID: 7927788
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization of immunotoxins active against ovarian cancer cell lines.
    Pirker R; FitzGerald DJ; Hamilton TC; Ozols RF; Laird W; Frankel AE; Willingham MC; Pastan I
    J Clin Invest; 1985 Sep; 76(3):1261-7. PubMed ID: 3930572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pseudomonas exotoxin--immunotoxins.
    FitzGerald DJ; Willingham MC; Pastan I
    Cancer Treat Res; 1988; 37():161-73. PubMed ID: 2908624
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.
    Seetharam S; Chaudhary VK; FitzGerald D; Pastan I
    J Biol Chem; 1991 Sep; 266(26):17376-81. PubMed ID: 1910044
    [TBL] [Abstract][Full Text] [Related]  

  • 69. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
    Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
    Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.
    Baluna R; Sausville EA; Stone MJ; Stetler-Stevenson MA; Uhr JW; Vitetta ES
    Clin Cancer Res; 1996 Oct; 2(10):1705-12. PubMed ID: 9816120
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hybrid proteins between Pseudomonas exotoxin A and poliovirus protease 2Apro.
    Novoa I; Feduchi E; Carrasco L
    FEBS Lett; 1994 Nov; 355(1):45-8. PubMed ID: 7957960
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin.
    Puri RK; FitzGerald D; Leland P; Kozak RW; Pastan I
    Cell Immunol; 1992 Sep; 143(2):324-34. PubMed ID: 1511480
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins.
    Won J; Nam P; Lee Y; Choe M
    Biochem Biophys Res Commun; 2009 Apr; 382(1):15-20. PubMed ID: 19245794
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
    Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
    J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins.
    Roscoe DM; Pai LH; Pastan I
    Eur J Immunol; 1997 Jun; 27(6):1459-68. PubMed ID: 9209499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
    Kawakami K; Nakajima O; Morishita R; Nagai R
    ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recombinant single-chain immunotoxins against T and B cell leukemias.
    Kreitman RJ; Pastan I
    Leuk Lymphoma; 1994 Mar; 13(1-2):1-10. PubMed ID: 8025511
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibody internalization studied using a novel IgG binding toxin fusion.
    Mazor Y; Barnea I; Keydar I; Benhar I
    J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity.
    Wedekind JE; Trame CB; Dorywalska M; Koehl P; Raschke TM; McKee M; FitzGerald D; Collier RJ; McKay DB
    J Mol Biol; 2001 Dec; 314(4):823-37. PubMed ID: 11734000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.